Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Active salt of dipeptide compound of ornithine and aspartic acid and application thereof

A compound, ornithine technology, applied in the field of medicine, can solve the problems of undisclosed use, undisclosed active salt of ornithine and aspartic acid dipeptide compound, etc.

Inactive Publication Date: 2022-04-12
NANJING YOUKE BIOLOGICAL MEDICAL RES +3
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The prior art does not disclose active salts of ornithine and aspartic acid dipeptide compounds, nor does it disclose its use in the preparation of drugs for the prevention or treatment of hyperammonemia or liver disease, especially hepatic encephalopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Active salt of dipeptide compound of ornithine and aspartic acid and application thereof
  • Active salt of dipeptide compound of ornithine and aspartic acid and application thereof
  • Active salt of dipeptide compound of ornithine and aspartic acid and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] The preparation of embodiment 1 intermediate 1

[0041] Add 0.258g (6.45mmol, 3eq) of sodium hydroxide, 10ml of purified water and 0.5g (2.15mmol, 1eq) of N-δ-Boc-L-ornithine into a 100ml reaction flask, and add Boc anhydride at 0-10°C 0.563g (2.58mmol, 1.2eq) / 10ml THF solution, after the dropwise addition, stirred at room temperature. After the reaction was monitored by TLC until the reaction was complete, the temperature was lowered to below 10°C, dilute hydrochloric acid was added dropwise to pH 4-5, the aqueous phase was extracted with ethyl acetate (15ml×2), the ethyl acetate layers were combined, washed once with purified water, organic The phase was dried with anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain 0.81 g of intermediate 1 as a foamy solid crude product, and the yield was basically quantitative.

Embodiment 2

[0042] The preparation of embodiment 2 intermediate 1

[0043] Add 11.8g (296.5mmol, 5eq) of sodium hydroxide and 200ml of purified water into a 500ml three-necked flask, cool down to 0°C, add 10g (59.3mmol, 1eq) of L-ornithine hydrochloride, stir to dissolve, 0 A solution of Boc-anhydride (38.8g, 177.9mmol, 3eq) in tetrahydrofuran (200ml) was added dropwise at about ℃, and reacted at room temperature after the addition was complete. After TLC monitoring to the completion of the reaction, concentrate tetrahydrofuran under reduced pressure at 45°C, adjust the aqueous phase to about pH 4-5 with 1N hydrochloric acid, extract with ethyl acetate (100ml×2), combine the ethyl acetate layers, wash twice with purified water, and organic The phase was dried with anhydrous sodium sulfate, filtered and concentrated to dryness under reduced pressure at 45°C to obtain 20 g of white foamy solid, Intermediate 1, with a quantitative yield.

Embodiment 3

[0044] The preparation of embodiment 3 intermediate 2

[0045] In a 500ml round bottom flask, add intermediate 1 compound 18.0g (54.2mmol, 1eq), add 180ml tetrahydrofuran and stir to dissolve, then add N-hydroxysuccinimide 6.86g (59.6mmol, 1.1eq), stir to The temperature was lowered to about 0°C, and a solution of DCC (12.3g, 59.6mmol, 1.1eq) in tetrahydrofuran (100ml) was slowly added dropwise, and stirred at room temperature after the dropwise addition, solids slowly precipitated at room temperature, monitored by TLC until the reaction was complete , filtered with suction, and the filtrate was kept for use.

[0046] Take another 1000ml three-necked flask, add 7.9g (59.35mmol, 1.1eq) of L-aspartic acid, 200ml of purified water, 18.2g (21.66mmol, 4eq) of sodium bicarbonate and stir until the solid dissolves, then add dropwise at room temperature The remaining filtrate obtained in the previous step (i.e. the prepared activated ester solution), after the dropwise addition, was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides active salts of ornithine and aspartate dipeptide compounds, preparation methods thereof, pharmaceutical compositions comprising the active salts, and preparation of the dipeptide compounds or their active salts for preventing or treating hyperemia Use in the medicament of ammonia disease or liver disease, especially hepatic encephalopathy. The test results clearly show that the ornithine and aspartate dipeptide compounds and their active salts of the present invention can significantly reduce blood ammonia concentration after administration, and can significantly improve the memory secondary to TAA-induced liver injury in rats. It means that the dipeptide compound and its active salt have a certain therapeutic effect on hyperammonemia or liver disease, especially hepatic encephalopathy.

Description

technical field [0001] The present invention belongs to the field of medicine, and in particular relates to an active salt of an ornithine and aspartic acid dipeptide compound, a preparation method thereof, a pharmaceutical composition containing the active salt, and the dipeptide compound or its active salt in Use in the preparation of medicines for preventing or treating hyperammonemia or liver disease, especially hepatic encephalopathy. Background technique [0002] Hepatic encephalopathy (HE) is a complex neuropsychiatric disorder that occurs in a variety of clinical conditions such as acute or chronic liver disease and spontaneous portosystemic shunts. In the early stages of hepatic encephalopathy, subtle mental changes such as difficulty concentrating, confusion, and disorientation occur. In severe cases, hepatic encephalopathy can lead to stupor, coma, swelling of the brain (cerebral edema), and death. Accumulation of ammonia is thought to play an important role in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K5/068C07K1/02C07K1/18A61K38/05A61P1/16A61P3/00
Inventor 张峰朱素华聂鑫张建华薛峪泉刘春猛
Owner NANJING YOUKE BIOLOGICAL MEDICAL RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com